Therapeutic decision in S-DA and M-DA patients was guided by IGF-I levels and IGF-I+ tumour control despite collecting patient PROs in the study visit, showing that that clinical and analytical data collection may not be useful if it is not integrated and interpreted. Here, IGF1 is linked to neoplasm.